LEO Pharma and DKSH Partner to Deliver Products and Solutions to People in Asia with Skin Conditions and Thrombosis
29 Septiembre 2022 - 12:00AM
Business Wire
LEO Pharma and DKSH have entered into an agreement to bring
high-quality therapeutic products for dermatology and thrombosis to
patients across Asia. This agreement both supports LEO Pharma’s
strategy of building a simpler and more competitive organization
and DKSH Business Unit Healthcare’s strategic focus of
strengthening its regional footprint.
DKSH Business Unit Healthcare, a leading partner for healthcare
companies seeking to grow their business in Asia and beyond, has
partnered with LEO Pharma to bring high-quality therapeutic
products for dermatology and thrombosis to patients across
Asia.
Partnering in Hong Kong, Malaysia, Singapore, Taiwan, Thailand,
Vietnam, and the Philippines, the two companies seek to solidify
brand presence, grow market share, and ultimately improve patient
health outcomes in the region. Skin diseases can cause serious
physical and social discomfort for millions of patients around the
world whereas thrombosis can affect anyone regardless of their age,
race, gender, and ethnicity.
DKSH will support LEO Pharma by building dedicated sales and
marketing teams on the ground in Asia and managing logistics and
product distribution in these markets. The firm’s experienced teams
and broad distribution network will ensure LEO Pharma products
reach modern trade, traditional trade, hospitals, clinics, and
other medical channels, as well as patients in need across the
region.
LEO Pharma is a global company dedicated to advancing the
standard of care for the benefit of people with skin conditions,
their families and society. With decades of research and
development to advance the science of dermatology, LEO Pharma now
offers a wide range of innovative treatments and therapies for all
skin disease severities as well as thrombosis.
Khalid Aouidat, Vice President, responsible for commercial
activities in Southeast Asia at LEO Pharma commented: “At LEO
Pharma, we are dedicated to changing the standards of care for
people with skin diseases by bringing new innovative treatments
forward and making them easily accessible. Supporting this
ambition, we are delighted to be partnering with DKSH. Their
experience and strong regional footprint in Asia, as well as their
marketing and sales expertise should help to further strengthen LEO
Pharma’s brand and its continued growth.”
Bijay Singh, Head of Business Unit Healthcare at DKSH, said: “We
are committed to enriching people’s lives and improving healthcare
for all. The partnership with LEO Pharma strengthens our ambition
to become the preferred partner for clients to help patients in
Asia to have better access to high-quality and innovative products
and solutions. While we drive their growth across the region, LEO
Pharma can focus on researching and developing products and
solutions for people with skin conditions.”
About LEO Pharma LEO Pharma is a global company dedicated
to advancing the standard of care for the benefit of people with
skin conditions, their families and society. Founded in 1908 and
majority owned by the LEO Foundation, LEO Pharma has devoted
decades of research and development to advance the science of
dermatology, and today, the company offers a wide range of
therapies for all disease severities. LEO Pharma is headquartered
in Denmark with a global team of 5,200 people, serving millions of
patients across the world. In 2021, the company generated net sales
of EUR 1,339 million. www.leo-pharma.com
About DKSH DKSH’s purpose is to enrich people’s lives.
For more than 150 years, we have been delivering growth for
companies in Asia and beyond across our Business Units Healthcare,
Consumer Goods, Performance Materials, and Technology. As a leading
Market Expansion Services provider, we offer sourcing, market
insights, marketing and sales, eCommerce, distribution and
logistics as well as after-sales services. DKSH is a participant of
the United Nations Global Compact and adheres to its
principles-based approach to responsible business. Listed on the
SIX Swiss Exchange, DKSH operates in 36 markets with 33,100
specialists, generating net sales of CHF 11.1 billion in 2021. The
DKSH Business Unit Healthcare distributes pharmaceuticals, consumer
health and over-the-counter (OTC) products as well as medical
devices. With around 7,920 specialists, the Business Unit generated
net sales of CHF 5.6 billion in 2021. www.dksh.com/hec
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220928005502/en/
For more information, please contact:
DKSH Business Unit Healthcare Sheena Flannery
Director, Group Marketing sheena.flannery@dksh.com
LEO Pharma Henrik Heskjær hdtdk@leo-pharma.com